Live feed
Filing
SCHEDULE 13D
SCHEDULE 13D0001193125-26-458677·Fairmount Funds Management LLC
Schedule 13D ownership disclosure
InMed Pharmaceuticals Inc.
Common Stock, par value $0.0001 per share · CUSIP: 587157108
Event date: 2026-11-06
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Fairmount Funds Management LLCReported CIK 0001802528
Shares: 10,555,507 · Class: 19.99%
- Fairmount Healthcare Fund II L.P.Reported CIK 0001769651
Shares: 10,555,507 · Class: 19.99%
- Peter Evan HarwinReported CIK 0001663607
Shares: 10,555,507 · Class: 19.99%
- Tomas KiselakReported CIK 0001830177
Shares: 10,555,507 · Class: 19.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-458677
- Form type
- SCHEDULE 13D
- Filer
- Fairmount Funds Management LLC
- CIK
- CIK 1802528
- Filed
- Nov 12, 2026
- Reporting period
- Nov 06, 2026
- Description
- Schedule 13D beneficial ownership